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Pathogenic Yersinia species and Pseudomonas aeruginosa share a similar type III secretion/translocationsystem.
The translocation system consists of 3 secreted proteins, YopB/PopB, YopD/PopD, and LcrV/PcrV; the latter
is known to be a protective antigen. In an in vitro assay, the translocation system causes the lysis of erythrocytes
infected with wild-type (wt) P. aeruginosa. wt Y. enterocolitica is not hemolytic, but a multiknockout mutant
deprived of all the effectors and of YopN (DHOPEMN) is hemolytic. In the presence of antibodies against
PcrV and Y. pestis LcrV, the hemolytic activity of P. aeruginosa was inhibited. Similarly, the hemolytic activity
of DHOPEMN was inhibited in the presence of anti-LcrV antibodies. The assembly of the translocon, composed
of PopB/D and YopB/D proteins, was disturbed in immunoprotected erythrocyte membranes, mimicking the
phenotypes of V knockout mutants. Thus, protective antibodies against the V antigens of Yersinia species and
P. aeruginosa act at the level of the formation of the translocon pore in membranes of infected host cells by
blocking the function of LcrV/PcrV. The hemolysis assay could be adapted for high-throughput screening of
anti-infectious compounds that specifically target the type III translocon.
Injectisomes are complex nanomachines that allow path-
ogenic or symbiotic bacteria to inject proteins across the
membrane of eukaryotic host cells. They consist of a
basal body that contains a type III secretion (T3S) ap-
paratus and a stiff needle that can be extended by a
flexible pilus or filament [1, 2]. Upon contact with a
eukaryotic cell membrane, the injectisome secretes, pre-
sumably in a sequential manner, a set of proteins called
“translocators” and “intracellular effectors” [3, 4]. The
translocators are a group of, generally, 3 proteins that
are absolutely required for the proper delivery of the
effectors across the host cell membrane [3–12].
Pathogenic members of the genus Yersinia—for ex-
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ample, Y. pestis (the causative agent of plague) and the
enteric pathogens Y. enterocolitica and Y. pseudotuber-
culosis—share a common injectisome called “Ysc” and a
common set of translocators and effectors called “Yops.”
The translocators are called “YopB,” “YopD,” and “LcrV.”
The latter is a bona fide Yop; it has a different name
because it was discovered as a soluble protective antigen
linked to virulence (hence, it is named “V antigen”) 140
years ago [13, 14], long before the concept of T3S had
been shaped [15]. Interestingly, the opportunistic path-
ogen Pseudomonas aeruginosa, which is evolutionarily re-
mote from enterobacteriaceae, has a very similar injec-
tisome called “Psc” and a set of similar translocators
called “PopB,” “PopD,” and “PcrV” [16–18]. Both sets
of translocators have been shown to form pores in eryth-
rocytes (red blood cells [RBCs]) [5, 9], in eukaryotic cell
membranes [19, 20], and in liposomes [21]. Formation
of pores is readily detectable with wild-type (wt) P. aeru-
ginosa but not with wt Y. enterocolitica. Only Y. entero-
colitica mutants that are devoid of the effectors or of the
control protein YopN form readily detectable pores [5,
11, 20]. An interpretation of this observation is that trans-
located Yop effectors obstruct the translocation chan-
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Table 1. Bacterial strains.
Strains Relevant genotype or phenotype Reference
P. aeruginosa, CHA Mucoid, cytotoxic cystic fibrosis isolate [32]
Y. enterocolitica
E40 Wild-type strain with the plasmid pYV40 [39]
DHOPEMN pYV40 yopE21 yopHD41–352 yopOD65–558 yopP23 yopM23 yopN45 [11]
DHOPEMNV pYV40 yopE21 yopHD41–352 yopOD65–558 yopP23 yopM23 yopN45 lcrVD6–319 [11]
DHOPEMNVQ pYV40 yopE21 yopHD41–352 yopOD65–558 yopP23 yopM23 yopN45 lcrVD6–319 yopQ17 [20]
DHOPEMNB pYV40 yopE21 yopHD41–352 yopOD65–558 yopP23 yopM23 yopN45 yopBD89–217 [20]
DHOPEMND pYV40 yopE21 yopHD41–352 yopOD65–558 yopP23 yopM23 yopN45 yopDD121–165 [20]
DN pYV40 yopN45 [6]
NOTE. P. aeruginosa, Pseudomonas aeruginosa; Y. enterocolitica, Yersinia enterocolitica.
nel [5, 20]. However, it has also been shown that the Rho-GAP
activity of YopE prevents membrane damage in cells infected
with wt bacteria [22]. When YopN is missing, secretion is con-
tact independent and effectors are not efficiently translocated
[11]. The structure of the translocation pore, the stage during
which the translocation pore is inserted, and how it is connected
to the needle of the injectisome are not clear yet. It is tempting
to consider the translocation pore as an integral part of the
injectisome, but, unlike the needle, it could be assembled only
after contact with a target cell. It has been shown that PopB
and PopD are able to oligomerize in vitro and that their in-
teraction with lipids promotes the formation of ringlike struc-
tures with external and internal diameters of 80 and 40 A˚,
respectively [23]. Although PcrV is unable to interact with lipids
either in vitro or in vivo [9, 23], it is required for proper
assembly of the PopB/D translocon in membranes of infected
erythrocytes [9].
Y. pestis LcrV possesses a highly protective antigenic char-
acter, and antibody therapy against bubonic and pneumonic
plague has been shown to be effective when tested in animal
models of disease [24–26]. Similarly, in animal models, active
immunization with PcrV or passive immunization with anti-
V antibodies provides a high level of protection against lethal
P. aeruginosa infections [7, 27]. Furthermore, administration
of anti-PcrV F(ab′)2 in a P. aeruginosa–provoked sepsis model
reduced the inflammatory response and bacteremia levels [28].
Although the mechanism of action is not known, even in vitro,
anti-V antibodies prevent the cytotoxicity of bacteria toward
cultured cells [7, 29, 30].
In the present study, we examined the action of anti-V an-
tibodies on formation of the translocation pore in P. aeruginosa
and Y. enterocolitica hemolysis assays. It has already been shown
with P. aeruginosa that a high level of hemolysis can be obtained
at a low MOI (MOI, 1) within 1 h of coincubation. Another
advantage of this model is that RBCs are not a limiting factor,
and their membranes can be isolated after infection and ana-
lyzed for translocon proteins without being contaminated with
infecting bacteria [9, 31]. In the present study, we applied the
RBC assay to Yersinia species by using poly-Yop effector mu-
tants of Y. enterocolitica [20]. We demonstrate that the anti-
bodies against the V antigens, through their direct interaction
with V proteins, inhibit bacteria-induced hemolysis by acting
at the level of type III translocon assembly in host cell mem-
branes, for both pathogenic species.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains
used in the present study are listed in table 1. The P. aeruginosa
strain used was the cytotoxic cystic fibrosis isolate CHA [19,
32]. P. aeruginosa were grown either on Pseudomonas isolation
agar (Difco) plates or in liquid Luria broth (LB) medium at
37C with agitation. All the mutants of Y. enterocolitica used
were derived from the strain E40, a strain from serotype O:9
[4, 11]. Y. enterocolitica strains were inoculated to an OD600 of
0.1 and cultivated in brain-heart infusion broth (ICN) for 3 h
at 37C. In vitro, secretion of Y. enterocolitica was triggered by
sodium oxalate [11].
Production and purification of antibodies. The produc-
tion and purification of the rabbit-derived anti-PcrV, anti-
PopB, and anti-PopD polyclonal antibodies (PAbs) have been
described elsewhere [9, 23]. MAb166 [27] was provided by D.
W. Frank (Medical College of Wisconsin). The LcrV coding se-
quence was obtained from genomic DNA of the Y. pestis strain
EV76 (gift from E. Carniel, Pasteur Institute, Paris) by poly-
merase chain reaction (PCR) using the primers 5′-GATAAGAA-
TTCGAGCCTACGAACAAAACCCA-3′ and 5′-AAGGATCGT-
CGACTTACATAATTACCTCGTGTCA-3′. The PCR product
was digested with EcoRI and SalI and cloned into the expression
plasmid pGEX-6P-2 (Amersham Biosciences). A soluble gluta-
thione-S-transferase (GST)–LcrV fusion was produced in Esch-
erichia coli and purified on GSTrap (Amersham Biosciences). The
GST-LcrV protein fusion bound on the column was cleaved with
PreScission Protease (Amersham), resulting in the elution of pu-
rified LcrV. Three CD1 mice were immunized with 100-mL in-
tramuscular injections of 10 mg of purified LcrV in PBS con-
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Figure 1. Immunoprotection of red blood cells (RBCs) against Pseudomonas aeruginosa–induced hemolysis. A, Lysis of RBCs by type III secretion
of P. aeruginosa (MOI, 1) at 37C, after 1 h in the presence of different antibodies added to the bacteria before coincubation. Anti-PcrV and anti-
PopB polyclonal antibodies (PAbs) were affinity purified from rabbit serum, anti-LcrV PAbs were purified on protein A from mouse serum, and anti-
PopD was total rabbit serum. MAb166 is a protective monoclonal antibody against PcrV [27]. B, Titration of protective antibodies by recombinant LcrV
(rLcrV) or PcrV (rPcrV). The hemolysis assay was performed in the presence of immunoprotective anti-PcrV PAbs added in quantities necessary to
achieve 90%–100% protection. Purified rPcrV and rLcrV proteins were added to the assay, and hemolysis was measured after 1 h of incubation.
taining 2% alhydrogel (Superfos Biosector) and 10 mg of CpG
oligonucleotide [33] as adjuvant. In each mouse, after 2 im-
munizations separated by a 2-week interval, the ELISA titer (the
highest dilution giving twice the optical density obtained with
naive CD1 serum) of anti-LcrV serum antibodies was 11:50,000.
For production of anti-LcrV PAbs, the best-responding mouse
was given an intraperitoneal (ip) booster injection of the same
respective amounts of LcrV, alhydrogel, and CpG, followed 5
days later by a final ip injection containing LcrV, CpG, and
TG180 sarcoma cells. The ascitis fluid was collected 155 10
week later, and IgG was purified on protein A (Mab Trap; Amer-
sham). The BCA protein assay kit (Pierce) was used to determine
the concentration of purified antibodies.
Hemolysis assays and immunoprotection experiments. He-
molysis assays were performed as described elsewhere [9].
Briefly, sheep RBCs (Eurobio) were washed 3 times in PBS (pH
7.4) (150 mmol/L NaCl) and resuspended in RPMI 1640 me-
dium (Sigma) at RBCs/mL at 4C. Bacteria were grown85 10
in LB to an OD600 of 1.0, centrifuged, and resuspended in RPMI
1640 at bacteria/mL. Hemolysis assays were initiated85 10
by mixing 100 mL of RBCs and 100 mL of bacteria in round-
bottom 96-well plates, which were then centrifuged at 2000 g
for 10 min and incubated for 1 h at 37C. The release of
hemoglobin was measured, and the percentage of hemolysis
was calculated as described elsewhere [31]. Immunoprotection
experiments were performed by incubating bacteria for 45 min
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Figure 2. Assembly of the Pseudomonas aeruginosa PopB/D translocon in immunoprotected red blood cell (RBC) membranes. A, RBC membranes
isolated on sucrose density gradients after performance of hemolysis assays in the presence of either protective anti-PcrV polyclonal antibodies (PAbs)
or anti-PopB PAbs. B, RBC membranes isolated after hemolysis assay with the wild-type (wt) and the pcrV mutant (DV) [9]. The translocon content
of PopB, PopD, and PcrV within membranes was analyzed by Western blotting.
with different concentrations of antibodies at room tempera-
ture, before the standard hemolytic assay. Negative controls
included corresponding preimmune rabbit serum. In titration
experiments, a constant concentration of 5 ng/mL PAbs was
added to bacteria, then increasing amounts of the recombinant
PcrV or LcrV were incubated with the bacteria-PAb mixture
for 45 min at room temperature.
RBC membrane isolation. RBCs were resuspended in Tris-
saline (30 mmol/L Tris and 150 mmol/L NaCl [pH 7.5]) at
cells/mL. Before the infection, bacteria were10 91 10 3 10
incubated with 180 mg of PAbs in 700 mL of Tris-saline buffer
for 45 min at room temperature. Then, hemolytic reactions
were prepared in 50-mL conical tubes. The mixture of bacte-
ria and antibodies was mixed with 300 mL of RBCs at 11010
cells/mL and 1 mL of a 2 protease inhibitor cocktail (Com-
plete; Roche). Samples were centrifuged at 2000 g for 10 min
at room temperature and incubated for 1 h at 37C. Hemolysis
was assessed spectrophotometrically, as described above. Then,
3 mL of distilled water at 4C was added to each sample to
lyse all RBCs, and these were vortexed and centrifuged again
to remove bacteria. The RBC membranes were isolated by flo-
tation on a sucrose density gradient, as described elsewhere [9].
The material at the 44%/25% sucrose interface was collected,
diluted in Tris-saline, and concentrated by centrifugation in a
TLA-100.3 rotor (Beckman) at 450,000 g for 20 min at 4C.
The pellets were resuspended in Laemmli sample buffer and
analyzed by Western blotting.
Immunoblotting analysis. Immunoblotting analysis was
performed with primary PAbs against YopB (gift from A˚. Fors-
berg, Umea˚ University), PopB, PopD, and PcrV [9]; monoclo-
nal antibodies (MAbs) against YopD [20] and LcrV [11]; and
a secondary antibody conjugated to horseradish peroxidase (Sig-
ma). Membranes were developed by use of an enhanced chem-
iluminescence kit (Amersham Biosciences).
RESULTS AND DISCUSSION
Since PcrV has been found to be necessary for assembly of
PopB/D pores in RBC membranes [9], we asked whether an-
tibodies against PcrV would interfere with the PopB/D-depen-
dent hemolysis induced by cytotoxic P. aeruginosa strain CHA.
Affinity-purified PAbs against translocator proteins PopB and
PopD did not inhibit hemolysis. Concentrations of both an-
tibodies up to 50 ng/mL had no protective effect. In contrast,
affinity-purified anti-PcrV PAbs [9] mixed with either bacteria
or RBCs before infection inhibited hemolysis in a dose-depen-
dent manner (figure 1A). Concentrations of antibodies as low
as 0.25 ng/mL were able to reduce P. aeruginosa–induced lysis
by 50%. Increasing the concentration of antibodies up to 10
ng/mL in the infection assay resulted in complete protection of
RBCs from lysis. MAb166 is an anti-PcrV MAb that has been
shown to protect mice from lethal P. aeruginosa infection [27].
In the hemolysis assay, MAb166 prevented hemolysis, but an
18-fold greater concentration of MAb166 than of PAbs was
required to obtain 50% inhibition. The higher neutralization
activity of the PAbs could be due to the binding of several PcrV
epitopes or to a higher affinity of some antibody component,
compared with MAb166. The former hypothesis is favored be-
cause, in a competition ELISA, a 100-fold excess of PAb did
not hinder the binding of MAb166 to recombinant PcrV (rPcrV)
(data not shown). This could have practical importance, be-
cause efficient neutralization of PcrV by MAbs would then re-
quire a combination of several MAbs, as seems to be the case
for botulinum toxin type A [34].
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Figure 3. Lysis of red blood cells (RBCs) by the Ysc-Yop type III
secretion system from Yersinia enterocolitica. The removal of YopQ min-
imizes the negative effect of the lcrV deletion on synthesis of YopB and
YopD [11]. A, Percentage hemolysis after 1 h of contact (MOI, 1). B, C,
and D, Western blot analysis of YopB, YopD, and LcrV performed on
intrabacterial proteins (B), the total amount of proteins secreted by the
bacteria during the infection (C), and proteins inserted into the membranes
of erythrocytes (D). wt, wild-type bacteria; DHOPEMN, a multi-effector
Ca2+-blind knockout [20]; DHOPEMNB, DHOPEMN lacking translocator
YopB [20]; DHOPEMND, DHOPEMN lacking translocator YopD [20];
DHOPEMNV, DHOPEMN lacking translocator LcrV [11]; DHOPEMNVQ,
DHOPEMNV lacking YopQ; DN, wt lacking regulator YopN [6].
LcrV from Yersinia species and PcrV from P. aeruginosa share
41% amino acid identity [16], and they most likely share the
same function in the assembly of the translocon. We raised mouse
PAbs against recombinant LcrV (rLcrV) from Y. pestis. Similar
to anti-PcrV PAbs and MAb166, anti-LcrV PAbs inhibited P.
aeruginosa–induced hemolysis (i.e., 50% inhibition was obtained
with 10 ng/mL anti-LcrV PAbs). In summary, these data show
that the PAbs against PcrV and LcrV, as well as the protective
MAb166, hinder cytotoxic P. aeruginosa from lysing RBCs.
LcrV and PcrV are surface-exposed antigens ([29, 35] and I.A.,
unpublished data) and, therefore, are probably accessible to an-
tibodies. To further confirm that the protection against hemolysis
was due to the direct interaction between antibodies and the
antigen during the infection process, we set up competition ex-
periments in which the antibodies necessary to achieve 90%–
100% protection were kept constant and increasing amounts of
the recombinant antigen were added to the infection mixture.
With rPcrV, as few as 3–4 molecules/10 molecules of antibodies
were sufficient to restore 50% hemolysis, showing that the pro-
tection is due to direct PcrV/antibody interaction (figure 1B).
RBC lysis occurs by osmotic shock following the formation
of PopB/D pores within erythrocyte membranes. Since PcrV is
required for formation of functional Pop pores, we addressed
the question of whether PopB/D inserts into membranes in the
presence of anti-V antibodies. The hemolysis assay was scaled
up, and antibodies were added at levels necessary to achieve
90%–100% protection. After 1 h of incubation, the RBCs were
lysed by the addition of water, and the membranes were purified
by sucrose density gradient, as described elsewhere [9]. The
purified membranes were examined for the presence of Pop
translocators by Western blotting. P. aeruginosa–infected RBC
membranes contained both translocators, PopB and PopD, as
reported elsewhere (figure 2) [9]. Notably, in the presence of
anti-PcrV PAbs, PopD protein was absent from infected RBC
membranes (figure 2), corroborating the phenotype of the PcrV
knockout bacteria that were unable to assemble the functional
translocon (figure 2) [9]. It should be noted that systematically
less PopB could be detected in membranes purified from these
immunoprotection experiments. Antibodies against PopB were
not able to disturb PopB/D pores inserted into host membranes
(figure 2), which is in agreement with the incapacity of these
antibodies to immunoprotect infected RBCs. These results show
that anti-PcrV antibodies either block the proper insertion of
pore-forming proteins or destabilize them within membranes.
That PopB was still found in immunoprotected membranes, al-
though it was unable to form functional pores, suggests that
protective antibodies do not prevent contact between the host
cell and the bacterial injectisome.
Since the serum raised against the Y. pestis rLcrV prevented,
to some degree, P. aeruginosa T3S–induced hemolysis, we ap-
plied the hemolysis test to several Y. enterocolitica strains. As
was already reported by several authors [5, 20], the wt Yersinia
strains had very low hemolytic activity, even when the bacteria–
host cell contact was forced with centrifugation. Indeed, no
detectable hemolysis could be observed at 1 h after infection
(figure 3A). Neyt et al. [20] and Marenne et al. [11] reported
that, in contrast to the wt strain, the mutant strainDHOPEMN,
which lacks T3S effectors (YopH, -O, -P, -E, and -M) as well
as the control protein YopN [36], provokes macrophage cell
lysis through the formation of pores presumably constituted
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Figure 4. Immunoprotection of red blood cells (RBCs) fromDHOPEMN-
induced hemolysis, by use of anti-LcrV or anti-PcrV antibodies. A, Per-
centage hemolysis in the presence of various amounts of affinity-purified
anti-PcrV polyclonal antibodies (PAbs) and protein A–purified anti-LcrV
PAbs. B, Western blot analysis of YopB, YopD, and LcrV performed on
the membranes of erythrocytes either not protected or protected by anti-
LcrV antibodies. DHOPEMN, a multi-effector Ca2+-blind knockout [20].
by the translocators YopB and YopD. Notably, in the standard
RBC assay, DHOPEMN bacteria lysed ∼30% of the erythrocytes
within 1 h of coincubation (MOI, 1), a value lower than that
observed with cytotoxic P. aeruginosa but still very significant
(figure 3A). DHOPEMN-induced hemolysis was dependent on
the presence of LcrV, since the mutant DHOPEMNV showed
only a basal level of hemolysis. In addition, LcrV was not di-
rectly hemolytic to RBCs, since the mutants DHOPEMNB and
DHOPEMND, which secrete the same amounts of LcrV as wt
bacteria, were not hemolytic. This result is in agreement with
data showing that P. aeruginosa strains that secrete PcrV are
nonhemolytic [9]. lcrV mutants are known to produce less YopB
and YopD, compared with wt bacteria [37–39], and this effect
can be attenuated by also mutating yopQ (figure 3C) [11]. We
thus also tested a DHOPEMNVQ mutant in the hemolysis
assay, and it was also found to be nonhemolytic (figure 3A),
showing that the lack of hemolysis observed withDHOPEMNV
was not due to insufficient secretion of YopB and YopD but
was directly due to the absence of LcrV (figure 3C).
Since PcrV is required for correct formation of PopB/D
pores, we addressed the function of LcrV in Y. enterocolitica.
RBC membrane fractions were examined for the presence of
the translocators after infection with the same strains of Y.
enterocolitica (figure 3D). Only YopD was readily detectable in
membranes of RBCs infected with wt bacteria. In contrast, YopB
and YopD were readily detectable in membranes of RBCs in-
fected with DHOPEMN and DN bacteria. This difference re-
flects the fact that wt bacteria produce and secrete less Yops on
contact with RBCs than do yopN mutant bacteria, which are
deregulated for Yop secretion (figure 3B and 3C) [36]. This
shows that centrifugation-achieved contact with RBCs does not
trigger optimal Yop secretion of wt bacteria. Both YopB and
YopD were detected in membranes of RBCs infected with
DHOPEMNVQ, but the amount of both translocators, espe-
cially YopB, was reduced, compared with that in DHOPEMN
orDN bacteria. This may simply reflect the fact thatDHOPEMNVQ
bacteria secrete less YopB/D than do DHOPEMN bacteria, but
it should be noted that they secrete at least as much YopB as
do wt bacteria (figure 3C). Nevertheless, although both YopB
and YopD were detected in the membrane, no pore was formed.
This suggests that, although LcrV is necessary for the proper
assembly of the YopB/D pore in the host cell membrane, it is
not necessary for the insertion of the translocators within host
membranes.
Anti-LcrV antibodies and anti-PcrV antibodies were then
tested for their capacity to protect erythrocytes from hemolysis
by DHOPEMN. As can be seen in figure 4A, anti-LcrV PAbs
were capable of protecting RBCs. The specific anti-LcrV serum
was as immunoprotective as were the PcrV PAbs in the P. aeru-
ginosa/RBC assay. However anti-PcrV PAbs had no protective
effect on DHOPEMN-induced hemolysis, suggesting that, al-
though some epitopes are shared by LcrV and PcrV, other neu-
tralization epitopes are unique to LcrV.
Next, we addressed the question of whether YopB/D pores
are formed in the presence of anti-LcrV antibodies.DHOPEMN
bacteria were preincubated for 30 min with antibodies at levels
necessary to achieve 90%–100% protection. Immunoprotected
membranes were purified and examined for the presence of the
translocators by Western blotting. The amount of YopB was se-
verely reduced in the presence of protective antibodies. It should
be noted that less YopD could be detected in immunoprotected
membranes (figure 4B). This suggests that anti-LcrV antibodies,
similar to anti-PcrV antibodies, prevent the assembly of the
functional translocation pore.
PcrV/LcrV protective antigens would thus act as extrabac-
terial chaperones or scaffolds in the sense that they would bind
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unfolded PopB/YopB and PopD/YopD emerging from the bac-
terium and ensure their correct folding and assembly into a
functional pore. This hypothesis, which is supported by the
fact that the T3S apparatus exports unfolded proteins [40], is
compatible with the known localization of LcrV at the bacterial
surface [29, 35]. It implies that the V antigen interacts, at least
transiently, with the B and D antigens, which is in agreement
with the observation of Sarker et al. [39]. However, it does not
imply that the V antigen remains bound to the assembled pore
and, thus, is not contradictory to results showing the absence
of direct interactions between PcrV and Pop proteins folded
in vitro [9, 23]. Finally, although it is inconsistent with the idea
that the purified LcrV forms channels on its own, the chaperone
or scaffold hypothesis is compatible with the observation that
LcrV determines the size of the pore [10, 18].
In conclusion, we have demonstrated that the protective an-
tibodies against the V antigens (PcrV and LcrV) of P. aeruginosa
and Yersinia species act by preventing the assembly of a func-
tional type III translocon in host cell membranes. In addition,
our work has shown that the hemolysis assay is well suited for
study of the function of the type III translocon and could be
adapted for screening of anti-infectious molecules that specif-
ically target bacterial toxin translocons.
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